Solventum Co. (NYSE:SOLV) Shares Sold by Centiva Capital LP

Centiva Capital LP trimmed its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 42.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,184 shares of the company's stock after selling 5,958 shares during the period. Centiva Capital LP's holdings in Solventum were worth $541,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of SOLV. Stonebridge Financial Group LLC purchased a new position in shares of Solventum in the 4th quarter worth $26,000. Crews Bank & Trust bought a new position in Solventum during the 4th quarter valued at about $32,000. Synergy Asset Management LLC purchased a new stake in Solventum in the 4th quarter worth about $35,000. Spire Wealth Management bought a new stake in Solventum in the fourth quarter worth about $37,000. Finally, Global Trust Asset Management LLC boosted its position in shares of Solventum by 137.5% during the fourth quarter. Global Trust Asset Management LLC now owns 570 shares of the company's stock valued at $38,000 after buying an additional 330 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SOLV shares. Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. Mizuho boosted their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. The Goldman Sachs Group raised their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. Piper Sandler decreased their target price on shares of Solventum from $80.00 to $78.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Wells Fargo & Company upped their target price on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Solventum presently has an average rating of "Hold" and an average price target of $79.00.

Solventum Stock Performance

SOLV stock traded down $2.57 during midday trading on Wednesday, hitting $70.95. 1,400,643 shares of the stock traded hands, compared to its average volume of 1,265,530. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock's fifty day simple moving average is $70.07 and its 200-day simple moving average is $71.29. The firm has a market cap of $12.27 billion and a P/E ratio of 32.85.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.15. The business had revenue of $2.07 billion for the quarter, compared to analysts' expectations of $2.02 billion. The business's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.08 EPS. On average, analysts expect that Solventum Co. will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.